Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 15, 2009, Pages 4441-4445

  Hammond, Marlys ^a   Washburn, David G ^a   Hoang, Tram H ^a   Manns, Sharada ^a   Frazee, James S ^a   Nakamura, Hiroko ^b   Patterson, Jaclyn R ^a   Trizna, Walter ^a   Wu, Charlene ^a   Azzarano, Leonard M ^a   Nagilla, Rakesh ^a   Nord, Melanie ^a   Trejo, Rebecca ^a   Head, Martha S ^a   Zhao, Baoguang ^a   Smallwood, Angela M ^a   Hightower, Kendra ^a   Laping, Nicholas J ^a   Schnackenberg, Christine G ^a   Thompson, Scott K ^a  

^a GLAXOSMITHKLINE   (United States)

^b Molecular Discovery Research   (United States)

Author keywords

Glucuronidation; Kinase inhibitor; Serum and glucocorticoid regulated kinase; SGK1

Indexed keywords

4 (5 PHENYL 1H PYRROLO[2,3 B]PYRIDIN 3 YL)BENZOIC ACID; [4 [5 (2 NAPHTHALENYL) 1H PYRROLO[2,3 B]PYRIDIN 3 YL]PHENYL]ACETIC ACID; CARBOXYLIC ACID; GLUCURONIC ACID; PHENOL; PROTEIN SERINE THREONINE KINASE INHIBITOR; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SERUM AND GLUCOCORTICOID REGULATED KINASE 1 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; GLUCURONIDATION; IN VIVO STUDY; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ENZYME INHIBITORS; GLUCOCORTICOIDS; GLUCURONIC ACID; IMMEDIATE-EARLY PROTEINS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MOLECULAR CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 67649965634     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.05.051     Document Type: Article

References (17)

1. Pearce D., and Kleyman T.R. J. Clin. Invest. 117 (2007) 592
2. Wulff P., Vallon V., Huang D.Y., Volkl H., Yu F., Richter K., Jansen M., Schlunz M., Klingel K., Loffing J., Kauselmann G., Bosl M.R., Lang F., and Kuhl D. J. Clin. Invest. 110 (2002) 1263
3. 50 was calculated from these data using GraphPad Prism 3 Software (GraphPad Software, San Diego, CA).
4. Nakhoul N.L., Hering-Smith K.S., Gambala C.T., and Hamm L.L. Am. J. Physiol. 275 (1998) F998
5. Dutton G.J. Glucuronidation of Drugs and Other Compounds (1980), CRC Press, Boca Raton p 268
6. Roberts M.S., Magnusson B.M., Burczynski F.J., and Weiss M. Clin. Pharmacokinet. 41 (2002) 751
7. Crystallographic data has been deposited in the PDB with deposition codes 3HDM for compound 1 and 3HDN for compound 2.
8. 1H NMR.
9. +.
10. Although the introduction of steric bulk near the site of glucuronidation would appear to be a common strategy for reducing conjugate formation, extensive literature searching turned up only a single report of such an observation:. Franklin T.J., Jacobs V.N., Jones G., and Ple P. Drug Metab. Dispos. 25 (1997) 367
11. +.
12. Bennetau B., Mortier J., Moyroud J., and Guesnet J.L. J. Chem. Soc., Perkin Trans.1 (1995) 1265
13. 3) d 7.31 (d, 2H, J = 8 Hz), 7.08 (d, 2H, J = 8 Hz), 3.70 (3H, s), 3.67 (s, 2H), 1.36 (s, 12H).
14. +.
15. Frazee, J. S.; Hammond, M.; Kano, K.; Manns, S.; Nakamura, H.; Thompson, S. K.; Washburn, D. G. WO 06/063167, 2006.
16. The use of compound 18, a.k.a. GSK650394, as an in vitro tool to elucidate the role of SGK-1 in different systems has been reported elsewhere:. Sherk A.B., Frigo D.E., Schnackenberg C.G., Bray J.D., Laping N.J., Trizna W., Hammond M., Patterson J.R., Thompson S.K., Kazmin D., Norris J.D., and McDonnell D.P. Cancer Res. 68 (2008) 7475
17. Saad S., Agapiou D.J., Chen X.M., Stevens V., and Pollock C.A. Nephrol. Dial. Transplant. 24 (2009) 1130